Moreover, the punicalagin-induced reduction of IL-1β transcription and secretion were observed in vivo, which indicates the possibility of punicalagin being used for the alleviation of psoriasis symptoms through the IL-1β targeting mechanism that represents a promising strategy for treating psoriasis (Table 11) [55]. This evidence concerns the gene IL1B and psoriasis.